Management of Type 2 Diabetes and Obesity

Introduction to Metformin and Phentermine

Metformin is a cornerstone first-line therapy for type 2 diabetes, providing modest weight loss and favorable effects on glycemic control without causing weight gain, and is associated with fewer hypoglycemic episodes compared to other agents, as recommended by the American College of Physicians and the American Diabetes Association 1, 1
Metformin can be considered in overweight patients with type 2 diabetes without cardiovascular disease and at moderate cardiovascular risk, typically producing modest weight loss of approximately 3% of body weight 2, 3

Phentermine is FDA-approved for short-term use (≤12 weeks) as an adjunct to lifestyle modifications for weight loss, with typical dosing up to 37.5 mg daily, and should be avoided in patients with a history of cardiovascular disease, uncontrolled hypertension, glaucoma, and history of substance use disorder 4, 3, 5
Phentermine should be limited to short-term use (≤12 weeks) with close monitoring, and discontinued if <5% weight loss is achieved after 12 weeks or at least 4 days before procedures requiring general anesthesia 4, 6, 2, 5
The strength of evidence for phentermine use is rated as moderate, due to limited long-term safety data 4

The combination of metformin and phentermine is not recommended for routine use in type 2 diabetes with obesity, but may be considered as an alternative approach if cost or access issues limit the use of GLP-1 receptor agonists, as recommended by the American Association of Clinical Endocrinologists 7
GLP-1 receptor agonists (like semaglutide or tirzepatide) are the preferred pharmacotherapy for weight management in patients with type 2 diabetes who are overweight or obese, due to their greater weight loss efficacy (9.6-14.7% reduction) and added cardiometabolic benefits, compared to phentermine (approximately 7.4% reduction) 6, 5
SGLT-2 inhibitors or GLP-1 receptor agonists should be considered regardless of baseline HbA1c for patients with additional cardiovascular risk factors, as recommended by the American Diabetes Association and the European Association for the Study of Diabetes 8, 9
SGLT-2 inhibitors are preferred for patients with heart failure or chronic kidney disease, according to the American Heart Association and the European Society of Cardiology 8, 9
GLP-1 receptor agonists show greater benefit for atherosclerotic cardiovascular disease reduction, as found by the American College of Cardiology 8

Regular monitoring of blood pressure and heart rate is recommended during phentermine use, with evaluation of weight loss at 12 weeks, as recommended by the American Heart Association 4
Phentermine is contraindicated in patients with a history of cardiovascular disease, uncontrolled hypertension, glaucoma, or history of substance use disorder, and should be used with caution in patients with a history of cardiovascular risk factors 4, 3, 5

Weight management through comprehensive lifestyle interventions remains the cornerstone of type 2 diabetes management, with pharmacotherapy serving as an adjunct to these efforts, as recommended by the Academy of Nutrition and Dietetics and the American Diabetes Association 1, 6
The American Diabetes Association recommends a comprehensive approach to type 2 diabetes management, including lifestyle modifications, pharmacotherapy, and regular monitoring, with a strength of evidence rated as high 6
Regular physical activity (at least 150 minutes per week of moderate-intensity or 75 minutes of vigorous-intensity) is strongly recommended to improve glycemic control and reduce cardiovascular risk, according to the American Heart Association 10
Intensive lifestyle interventions with caloric restriction can improve glycemic parameters, as recommended by the American Heart Association 10